SEARCH OF INHIBITORS OF HERPES VIRAL REPLICATION: 30 YEARS AFTER ACYCLOVIR Korovina A. N., Kuhanova M. K., Kochetkov S. N.

Details: Hits: 2843

ISSN 2410-7751 (Print)
ISSN 2410-776X (Online)

"Biotechnologia Acta" v. 6, no. 4, 2013
https://doi.org/10.15407/biotech6.04.078
Р. 78-85, Bibliography 33, Russian
Universal Decimal classification: 57.083.2+616.523

SEARCH OF INHIBITORS OF HERPES VIRAL REPLICATION: 30 YEARS AFTER ACYCLOVIR

Korovina A. N., Kuhanova M. K., Kochetkov S. N.

Engelhardt Institute of Molecular Biology of Russian Academy of Sciences, Moscow, Russia

Analysis of study and using of different chemical compounds as inhibitors of herpes virus replication is given in the review. However, it does not apply for full details of all the studies on active antiherpetic drugs finding. It’s been over 30 years since the discovery of the first antiherpetic drugs — acyclovir. Meanwhile, lots of active chemical compounds appeared that have been brought to the antiviral drugs. An essential understanding of strategies for finding drugs came in, one of which was establishment of depot forms of antiherpetic drugs. On the basis of the vast published experimental material the authors concluded that the study of the herpes virus and search for inhibitors of its replication is still an important issue and requires the efforts of chemists, biologists, pharmacists.

Key words: herpes virus, antiviral drugs acyclovir.

{accordion title="References" open="false"}

1. Coen D. M., Schaffer P. A. Nature reviews. Drug discovery. 2003, V. 2, P. 278–288.
https://doi.org/10.1038/nrd1065

2. Raab-Traub N. Current Opinion in Virology. 2012, V. 2, P. 453–458.
https://doi.org/10.1016/j.coviro.2012.07.001

3. Mesri E. A., Cesarman E., Boshoff C. Nature Rev. Cancer. 2010, V. 10, P. 707–719.
https://doi.org/10.1038/nrc2888

4. De Clercq E., Fiekd H. J. British J. Pharmacol. 2006, V. 147, P. 1–11.
https://doi.org/10.1038/sj.bjp.0706446

5. De Clercq E. J. Clin. Virol. 2001, V. 22, P. 73–89.
https://doi.org/10.1016/S1386-6532(01)00167-6

6. Bogani F., Boehmer P. E. Proc. Natl. Acad.?Sci. USA. 2008, V. 105, P. 11709–11714.
https://doi.org/10.1073/pnas.0806375105

7. Bogani F., Corredeira I., Fernandez V. J. Biol. Chem. 2010, V. 285, P. 27664-27672.
https://doi.org/10.1074/jbc.M110.131235

8. Liu S., Knafels J. D., Chang J. S. J. Biol. Chem. 2006, V. 281, P. 18193–18200.
https://doi.org/10.1074/jbc.M602414200

9. Terrell S. L., Coen D. M. J. Virol. 2012, V. 86, P. 11057–11065.
https://doi.org/10.1128/JVI.01034-12

10. Dorsky D., Crumpacker C. Antiviral research. 1987, V. 9, P. 92.

11. Elion G. B., Furman P. A., Fyfe J. A. Proc. Natl. Acad. Sci. USA. 1977, V. 74, P. 5716–5720.
https://doi.org/10.1073/pnas.74.12.5716

12. Schaeffer H. J., Beauchamp L., de Miranda P. Nature. 1978, V. 272, P. 583–585.
https://doi.org/10.1038/272583a0

13. Vadlapudi A. D., Vadlapatla R. K., Earla R. Pharm. Research. 2013.

14. Martin J. C., Dvorak C. A., Smee D. F. J. Med. Chem. 1983, V. 26, P. 759–761.
https://doi.org/10.1021/jm00359a023

15. Thust R., Tomicic M., Klocking R. Cancer gene therapy. 2000, V. 7, P. 107–117.
https://doi.org/10.1038/sj.cgt.7700106

16. Boyd M. R., Bacon T. H., Sutton D., Cole M. Antimicrobial agents and chemotherapy. 1987, V. 31, P. 1238–1242.
https://doi.org/10.1128/AAC.31.8.1238

17. Oberg B. Pharm. ther. 1989, V. 40, P. 213-285.

18. Helgstrand E., Eriksson B., Johansson N. G. Science. 1978, V. 201, P. 819–821.
https://doi.org/10.1126/science.210500

19. De Clercq E., Andrei G., Snoeck R. Nucleos., nucleot. nucl. acids. 2001, V. 20, P. 271–285.

20. Ivanov A. V., Andronova V. L., Galegov G. A., Jasko M. V. Bioorg. Chem. 2005, V. 31, P. 65–72.

21. Korovina A. N., Yasko M. V., Ivanov A. V. Vestnik Mosk. un-тa. Seriya 2. Khimiya. 2008, Т. 49, C. 108–111. (In Russian).

22. Karpenko I. L., Jasko M. V., Andronova V. L. Nucleos., nucleot. nucl. acids. 2003, V. 22, P. 319–328.

23. Skoblov Y. S., Karpenko I. L., Jasko M. V. Chem. Biol. Drug Des. 2007, V. 69, P. 429–434.
https://doi.org/10.1111/j.1747-0285.2007.00517.x

24. Gus’kova A. A., Skoblov M. Y., Korovina A. N. Chem. Biol. Drug Des. 2009, V. 74, P. 382–389.
https://doi.org/10.1111/j.1747-0285.2009.00874.x

25. Deev S. L., Yasko M. V., Karpenko I. L. Bioorg. Chem. 2010, V. 38, P. 265–270.
https://doi.org/10.1016/j.bioorg.2010.09.002

26. Gilbert C., Bestman-Smith J., Boivin G. Drug Resist Updat. 2002, V. 5, P. 88–114.
https://doi.org/10.1016/S1368-7646(02)00021-3

27. Korovina A. N., Gus’kova A. A., Skoblov M. Mol. biol. 2010, V. 44, P. 488–496.
https://doi.org/10.1134/S0026893310030118

28. Schnute M. E., Anderson D. J., Brideau R. J. Bioorg. Med. Chem. Lett. 2007, V. 17, P. 3349–3353.
https://doi.org/10.1016/j.bmcl.2007.03.102

29. Hwang Y. T., Smith J. F., Gao L., Hwang C. B. Virology. 1998, V. 246, P. 298–305.
https://doi.org/10.1006/viro.1998.9201

30. Suzutani T., Saijo M., Nagamine M. J. Clin. Microbiol. 2000, V. 38, P. 1839–1844.

31. Bestman-Smith J., Boivin G. J. Virol. 2003, V. 77, P. 7820–7829.
https://doi.org/10.1128/JVI.77.14.7820-7829.2003

32. Matthews J. T., Carroll R. D., Stevens J. T., Haffey M. L. J. Virol. 1989, V. 63, P. 4913–4918.

33. Matthews J. T., Terry B. J., Field A. K. Antivir. Res. 1993, V. 20, P. 89–114.
https://doi.org/10.1016/0166-3542(93)90001-Y

{/accordions}